# PTGDR

## Overview
The PTGDR gene encodes the prostaglandin D2 receptor, a G protein-coupled receptor (GPCR) that plays a crucial role in mediating the effects of prostaglandin D2 (PGD2) across various physiological and pathological processes. This receptor is involved in the regulation of immune responses, particularly in allergic reactions, and contributes to functions such as smooth muscle relaxation, vasodilation, and the modulation of pain perception and sleep. The PTGDR gene is expressed in a variety of immune cells, including lymphocytes and eosinophils, and its activation leads to increased intracellular cyclic adenosine monophosphate (cAMP) levels, triggering downstream signaling pathways (Matsuoka2007Prostaglandin; GarcíaSolaesa2014The). Clinically, PTGDR is associated with allergic and inflammatory conditions, such as asthma, and its expression is altered in certain cancers, highlighting its potential as a therapeutic target and biomarker (Kalmár2015DNA; CornejoGarcía2016Pharmacogenomics).

## Function
The PTGDR gene encodes the prostaglandin D2 receptor, a G protein-coupled receptor involved in various physiological processes. In healthy human cells, PTGDR is activated by prostaglandin D2 (PGD2) and some of its metabolites, leading to increased intracellular levels of cyclic adenosine monophosphate (cAMP). This activation can trigger pathways involving protein kinase A (PKA) and other signaling mechanisms, depending on the cell type (GarcíaSolaesa2014The). PTGDR is expressed in several cell types, including NK, Th1, and Th2 lymphocytes, dendritic cells, eosinophils, neutrophils, basophils, and certain epithelial cells (GarcíaSolaesa2014The).

The receptor plays a role in smooth muscle relaxation, vasodilation, reduction of ocular tension, inhibition of platelet aggregation, and regulation of pain perception and sleep (GarcíaSolaesa2014The). PTGDR is also significant in the immune response, particularly in allergic diseases, where it mediates the effects of PGD2 produced by mast cells during allergic reactions (Matsuoka2007Prostaglandin). The receptor's activation contributes to the regulation of sleep, body temperature, and hormone release, highlighting its importance in maintaining physiological homeostasis (GarcíaSolaesa2014The).

## Clinical Significance
The PTGDR gene, encoding the prostaglandin D2 receptor, is implicated in several allergic and inflammatory conditions, most notably asthma. Variations in the PTGDR promoter region have been associated with asthma susceptibility, as these polymorphisms can influence gene expression and response to environmental allergens (GarcíaSánchez2016Retinoic; GarcíaSolaesa2014The). Specific single nucleotide polymorphisms (SNPs) such as -441C>T, -549T>C, and -197T>C have been linked to asthma and other allergic conditions, including allergic rhinitis and atopic dermatitis (CornejoGarcía2016Pharmacogenomics). These genetic variants can affect the binding of transcription factors, altering PTGDR expression and contributing to the pathophysiology of these diseases (GarcíaSolaesa2014The).

In addition to asthma, PTGDR expression is significantly downregulated in colorectal adenoma and cancer, suggesting a role in the progression of these conditions. This downregulation is potentially due to DNA hypermethylation, indicating that PTGDR may serve as a biomarker for early detection or a target for therapeutic intervention in colorectal cancer (Kalmár2015DNA). The gene's involvement in these diverse conditions highlights its clinical significance in both allergic and oncological contexts.


## References


[1. (GarcíaSolaesa2014The) V. García-Solaesa, C. Sanz-Lozano, J. Padrón-Morales, L. Hernández-Hernández, A. García-Sánchez, M.L. Rivera-Reigada, I. Dávila-González, F. Lorente-Toledano, and M. Isidoro-García. The prostaglandin d2 receptor (ptgdr) gene in asthma and allergic diseases. Allergologia et Immunopathologia, 42(1):64–68, January 2014. URL: http://dx.doi.org/10.1016/j.aller.2012.12.002, doi:10.1016/j.aller.2012.12.002. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.aller.2012.12.002)

[2. (CornejoGarcía2016Pharmacogenomics) José A. Cornejo-García, James R. Perkins, Raquel Jurado-Escobar, Elena García-Martín, José A. Agúndez, Enrique Viguera, Natalia Pérez-Sánchez, and Natalia Blanca-López. Pharmacogenomics of prostaglandin and leukotriene receptors. Frontiers in Pharmacology, September 2016. URL: http://dx.doi.org/10.3389/fphar.2016.00316, doi:10.3389/fphar.2016.00316. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2016.00316)

[3. (Matsuoka2007Prostaglandin) Toshiyuki Matsuoka and Shuh Narumiya. Prostaglandin receptor signaling in disease. The Scientific World JOURNAL, 7:1329–1347, 2007. URL: http://dx.doi.org/10.1100/tsw.2007.182, doi:10.1100/tsw.2007.182. This article has 80 citations.](https://doi.org/10.1100/tsw.2007.182)

[4. (Kalmár2015DNA) Alexandra Kalmár, Bálint Péterfia, Péter Hollósi, Orsolya Galamb, Sándor Spisák, Barnabás Wichmann, András Bodor, Kinga Tóth, Árpád V. Patai, Gábor Valcz, Zsófia Brigitta Nagy, Vivien Kubák, Zsolt Tulassay, Ilona Kovalszky, and Béla Molnár. Dna hypermethylation and decreased mrna expression of mal, prima1, ptgdr and sfrp1 in colorectal adenoma and cancer. BMC Cancer, October 2015. URL: http://dx.doi.org/10.1186/s12885-015-1687-x, doi:10.1186/s12885-015-1687-x. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-015-1687-x)

[5. (GarcíaSánchez2016Retinoic) A García-Sánchez, E Marcos-Vadillo, C Sanz, L Hernández-Hernández, G Cerutti-Müller, F Marqués-García, F Lorente, M Isidoro-García, and I Dávila. Retinoic acid modulates ptgdr promoter activity. Journal of Investigational Allergology and Clinical Immunology, 26(4):249–255, July 2016. URL: http://dx.doi.org/10.18176/jiaci.0042, doi:10.18176/jiaci.0042. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.18176/jiaci.0042)